Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.61 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.57 |
| ▸ | GLP1R | P43220 | 5/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.56 |
| ▸ | GRPR | P30550 | 3/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.53 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578571 | 0.98 | RXFP1 (0.58) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL31453816 | 0.97 | RXFP1 (0.65) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL30874393 | 0.96 | RXFP1 (0.60) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL30874386 | 0.94 | RXFP1 (0.58) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL30598172 | 0.93 | RXFP1 (0.63) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL30076208 | 0.93 | GLP1R (0.63) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL3113818 | 0.92 | RXFP1 (0.54) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL29370686 | 0.91 | NPBWR1 (0.56) | RXFP1NPBWR1GRPRIL23RPTH1R | |
| SCHEMBL29373303 | 0.91 | GLP1R (0.65) | RXFP1NPBWR1GLP1RECE1MUS81 | |
| SCHEMBL30627035 | 0.90 | RXFP1 (0.66) | RXFP1NPBWR1GLP1RECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| CN-117098843-A | Subtilisin variants and uses thereof | 费森尤斯卡比有限公司 | 2023-11-21 | — | — | CN | claimed |
| WO-2025264809-A1 | CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| CN-111819191-B | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240247042-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | GLP1R, IAPP, GCG | RXFP1 271/4885NPBWR1 431/4885GLP1R 1/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | RXFP1 83/4885NPBWR1 188/4885GLP1R 1/4885 |
| US-20240247042-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | GLP1R, IAPP, GPR119 | RXFP1 93/4885NPBWR1 198/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.